!

COVID-19 Response

Access our COVID-19 Response homepage, with more information and resources during the COVID-19 pandemic, including what to do if you’re experiencing symptoms.

Research

Del/Dup Analysis by aCGH

Master
Content

Copy number variation refers to a large range of DNA rearrangement (deletion or duplication) which cannot be detected by conventional sequencing analysis. If sequencing test is negative, CNV analysis is highly recommended otherwise the testing result is inconclusive. Array-based comparative genomic hybridization (aCGH) is one of the best tools available to analyze CNV.

The John Welsh Cardiovascular Diagnostic Laboratory offers a CNV test that is specifically designed to enrich 500 genes related to cardiovascular diseases using Agilent aCGH platform. This test has been validated in our laboratory on many samples with known clinically relevant CNVs. It is designed to detect losses and gains representing deletions, duplications or amplifications of the cardiovascular genes included. This assay will not detect balanced translocations, inversions or point mutations that may be responsible for the clinical phenotype.

Heading

Reasons for Referral

Content

Molecular confirmation of the diagnosis of certain cardiovascular diseases.

Heading

Methodology

Content

Genomic DNA is analyzed for CNVs by aCGH (Agilent 4x180k).

Heading

Service Fees

Content
Service Fees

Service

Direct and Institutional Billing

CPT Codes

Single Gene

$1,200 per sample

81228

Multiple Genes or Panel(s)

$1,500 per sample

81228

Heading

Sensitivity

Content

This target enriched array can detect as small as 1 kb deletion or duplication in exonic regions.

Heading

Specimen Requirements

Content

Blood (preferred): EDTA (purple-top) tubes: Adult: 5 cc | Child: 5 cc | Infant: 2-3 cc
Tissue: Frozen (preferred), RNAlater
Other Body Fluids: Call to inquire

Download Printable PDF